Stepwise approach towards adoption of allergen immunotherapy for allergic rhinitis and asthma patients in daily practice in Belgium: a BelSACI-Abeforcal-EUFOREA statement

• Main Authors: P. W. Hellings, B. Pugin, G. Mariën, C. Bachert, C. Breynaert, D. M. Bullens, J. L. Ceuppens, G. Clement, T. Cox, D. Ebo, P. Gevaert, S. Halewyck, V. Hox, K. Ladha, R. Jacobs, P. Rombaux, R. Schrijvers, K. Speleman, X. Van der Brempt, L. Van Gerven, O. Vanderveken, B. Verhaeghe, K. Vierstraete, S. Vlaminck, J. -B. Watelet, J. Bousquet, S. F. Seys
• Format: Article
• Language: English
• Published: Wiley 2019-02-01
• Series: Clinical and Translational Allergy
• Subjects: Allergic rhinitis; Asthma; Allergen-specific immunotherapy; Belgium
• Online Access: http://link.springer.com/article/10.1186/s13601-019-0243-1

Abstract Allergic rhinitis (AR) affects 23–30% of the European population with equal prevalence reported in Belgium. Despite guidelines on the correct use of effective treatment, up to 40% of AR patients remain uncontrolled. Allergen immunotherapy (AIT) has been shown to improve the level of control up to 84% of patients being controlled by AIT. Recently, new guidelines for AIT have been published, supporting the clinical evidence for effectiveness of various subcutaneous and sublingual products for AIT in patients who are allergic to airborne allergens. AIT in AR patients not only reduces nasal and/or ocular symptoms but also induces tolerance and has preventive potential. Adoption of AIT into daily clinical practice in Belgium and other European countries is hampered primarily by reimbursement issues of each of the single products but also by several patient- and physician-related factors. Patients need to be better informed about the effectiveness of AIT and the different routes of administration of AIT. Physicians dealing with AR patients should inform patients on tolerance-inducing effects of AIT and are in the need of a harmonized and practical guide that supports them in selecting eligible patients for AIT, in choosing evidence-based AIT products and in following treatment protocols with proven efficacy. Therefore, a stepwise and holistic approach is needed for better adoption of AIT in the real-life setting in Belgium.